Literature DB >> 17924897

Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies.

N Rosencher1, M-P Bonnet, D I Sessler.   

Abstract

We propose recommendations to reduce the risk of haemorrhagic events associated with regional anaesthesia in patients treated with newer anticoagulants after orthopaedic surgery. The risk/benefit ratio should be individualised for each patient according to the type and dose of anticoagulant, the type of regional anaesthesia and patient risk factors. Neuraxial anaesthetic management strategy can be based on the pharmacokinetic properties of specific anticoagulants, including the time required to reach maximal concentration, half-life, and dose regimen. Central neuraxial blocks should not be performed and epidural catheters should not be removed until at least two half-lives after the last injection of anticoagulant, the half-life depending on renal function. After removing a catheter or after a haemorrhagic puncture, the timing of the next anticoagulant injection should be based on the time required for an anticoagulant dose to reach maximum activity. Vigilance remains paramount during the initial days after removal of a neuraxial catheter.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17924897     DOI: 10.1111/j.1365-2044.2007.05195.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  18 in total

1.  [Recommendations for the administration of conventional and new antithrombotic agents from the perspective of anesthesiology].

Authors:  W Gogarten; K Hoffmann; H Van Aken
Journal:  Unfallchirurg       Date:  2010-11       Impact factor: 1.000

Review 2.  [Minimizing perioperative risk - an interdisciplinary effort].

Authors:  Matthias Bock; Christian J Wiedermann
Journal:  Wien Med Wochenschr       Date:  2008

Review 3.  New anticoagulants: how to deal with treatment failure and bleeding complications.

Authors:  Rashid S Kazmi; Bashir A Lwaleed
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

4.  [Analysis of prophylactic effect of extended-duration anticoagulant drugs in elderly patients undergoing hip fracture].

Authors:  W Zhang; P X Zhang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-06-18

5.  New anticoagulants: perioperative considerations.

Authors:  Sibylle A Kozek-Langenecker
Journal:  Wien Med Wochenschr       Date:  2011-02

6.  [New oral anticoagulants in perioperative medicine].

Authors:  A Giebl; K Gürtler
Journal:  Anaesthesist       Date:  2014-04       Impact factor: 1.041

Review 7.  NOACs in Anesthesiology.

Authors:  Donat R Spahn; Jürg-Hans Beer; Alain Borgeat; Pierre-Guy Chassot; Christian Kern; François Mach; Krassen Nedeltchev; Wolfgang Korte
Journal:  Transfus Med Hemother       Date:  2019-01-29       Impact factor: 3.747

8.  Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials.

Authors:  Nadia Rosencher; Herbert Noack; Martin Feuring; Andreas Clemens; Richard J Friedman; Bengt I Eriksson
Journal:  Thromb J       Date:  2012-06-18

9.  Emerging antithrombotic agents for thromboprophylaxis, clinical potential and patient considerations.

Authors:  Lars C Borris
Journal:  J Blood Med       Date:  2010-07-05

10.  Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions.

Authors:  Jorge Ferreira; Daniel Ferreira; Miguel Viana-Baptista; Paulo Bettencourt; Rui Cernadas; Francisco Crespo
Journal:  Thrombosis       Date:  2012-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.